Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 22, 2015 1:42 PM ET

Biotechnology

Company Overview of Intrexon Corporation

Company Overview

Intrexon Corporation, a biotechnology company, operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; cell systems informatics; RheoSwitch inducible gene switch; AttSite Recombinases; protein engineering; mAbLogix; and laser-enabled analysis and processing. Intrexon Corporation has collaboration agreements with ZIOPHARM Oncology, Inc.; Synthetic Biologics, Inc.; Oragenics, In...

20374 Seneca Meadows Parkway

Germantown, MD 20876

United States

Founded in 1998

480 Employees

Phone:

301-556-9900

Key Executives for Intrexon Corporation

Chairman, Chief Executive Officer and President
Age: 60
Chief Financial Officer
Age: 50
Total Annual Compensation: $382.2K
Chief Operating Officer
Age: 49
Total Annual Compensation: $2.3M
Senior Vice President of Health Sector
Age: 42
Total Annual Compensation: $986.0K
Senior Vice President of Energy Sector
Age: 56
Total Annual Compensation: $341.0K
Compensation as of Fiscal Year 2014.

Intrexon Corporation Key Developments

Intrexon Seeks Acquisitions

Intrexon Corporation (NYSE:XON) will consider acquisitions. We continue to track to our ambitious expectations," commented Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon. "As the benefits of our technology platforms and business model accumulate, we expect to continue to drive operating and financial performance in such a way as to produce excellent capital efficiency, which will allow us to grow both organically and by acquisition.

Intrexon Corporation Announces Unaudited Consolidated Earnings Results for the First Quarter Results Ended March 31, 2015

Intrexon Corporation announced unaudited consolidated earnings results for the first quarter results ended March 31, 2015. For the quarter, the company reported total revenues of $3,849,000 against $7,854,000 a year ago. Operating loss was $87,123,000 against $17,872,000 a year ago. Income before income taxes was $26,599,000 against $3,555,000 a year ago. Net income attributable to Intrexon was $27,097,000 against $4,115,000 a year ago. Net income per share, diluted was $0.25 against $0.04 a year ago. EBITDA was $31,663,000 against $6,218,000 a year ago. Adjusted LBITDA was $11,309,000 against adjusted EBITDA of $17,585,000 a year ago. Adjusted LBITDA per diluted share was $0.11 against adjusted EBITDA per diluted share of $0.18 a year ago.

Intrexon Declares Special Stock Dividend, Date of Distribution Will Occur in Mid-June 2015

Intrexon’s Board of Directors declared a special stock dividend of 17,830,305 shares of ZIOPHARM common stock owned by Intrexon to its shareholders. The distribution of the special stock dividend will be made on the Distribution Date to all Intrexon shareholders of record on June 4, 2015. The date of distribution by Intrexon of the special stock dividend is contemplated to occur in mid-June 2015.

Similar Private Companies By Industry

Company Name Region
Asklepios BioPharmaceutical, Inc. United States
G.I. Windows, Inc. United States
Principia Biopharma Inc. United States
Indigo Biosciences, Inc. United States
Biocell Laboratories, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
March 10, 2015
AmpliPhi Biosciences Corporation
Merger/Acquisition
February 27, 2015
Okanagan Specialty Fruits Inc.
Merger/Acquisition
February 13, 2015
ActoGeniX
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Intrexon Corporation, please visit www.dna.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.